Mechanism of Action
PAC1 / VPAC Receptor Signaling
PACAP activates three G protein-coupled receptors: PAC1 (selective for PACAP), VPAC1 and VPAC2 (shared with VIP). PAC1 couples to Gs and Gq proteins, increasing cAMP and IP3/DAG. This triggers PKA and PKC activation, modulating neurotransmitter release, neuronal survival, and gene expression. The high selectivity of PACAP-38 for PAC1 over VIP receptors provides a degree of target specificity not available with VIP.
Neuroprotection and Neurogenesis
PACAP is one of the most potent neuroprotective agents identified to date. It prevents neuronal apoptosis following ischemia, oxidative stress, and excitotoxicity through anti-apoptotic gene regulation, BDNF induction, and mitochondrial membrane stabilization. PACAP also stimulates adult neurogenesis in the hippocampus and subventricular zone, with implications for neurodegenerative disease and stress resilience.
Research Summary
Migraine and Headache
Phase 2Intravenous PACAP-38 triggers migraine-like attacks in migraine patients but not healthy controls, establishing it as a key mediator of migraine pathophysiology. Anti-PACAP and anti-PAC1 antibodies are being developed as preventive migraine treatments, analogous to the anti-CGRP approach. Phase 2 trials of humanized anti-PAC1 antibodies showed significant reductions in monthly migraine days.
Cardioprotection
PreclinicalPACAP-38 reduces infarct size and improves cardiac function in ischemia-reperfusion injury models. It activates anti-apoptotic signaling in cardiomyocytes and reduces inflammatory cytokine production. PACAP knockout mice show increased ischemic injury, confirming its endogenous cardioprotective role.
Calculate your PACAP dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Migraine trigger (research model) | 10 pmol/kg/min | 20-min IV infusion | Intravenous |
| Neuroprotection (preclinical) | 100 pmol/kg | Single dose post-injury | IV or IP injection |
No approved therapeutic use. Anti-PAC1/anti-PACAP antibodies are the therapeutic development focus.
Interactions
Safety Profile
IV PACAP-38 causes flushing, tachycardia, and headache in healthy subjects, consistent with its vasodilatory and neuromodulatory actions. In migraine patients, infusion reliably triggers migraine attacks. The short plasma half-life limits systemic exposure duration. Direct therapeutic use of PACAP requires careful cardiovascular monitoring. Anti-PACAP antibody approaches avoid these acute vasodilatory effects.
References
- [1]Miyata A et al. (1989). Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochemical and Biophysical Research Communications, 164(1), 567-574.
- [2]Schytz HW et al. (2009). PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain, 132(1), 16-25.